Novo Nordisk’s amylin obesity drug keeps performing like Zepbound

Health

Novo Nordisk’s Amylin Obesity Drug Keeps Performing Like Zepbound

By STAT

Elaine Chen covers biotech, co-writes The Readout newsletter , and co-hosts STAT’s weekly biotech podcast, The Readout Loud . You can reach Elaine on Signal at elaineywchen.70. CHICAGO — Late-stage results of Novo Nordisk’s obesity candidate CagriSem ...Read more

Related Posts

7 Benefits of The Keto Diet

7 Benefits of The Keto Diet

Dec 30, 2020
A New Obesity Pill May Burn Fat Without Suppressing Appetite

A New Obesity Pill May Burn Fat Without Suppressing Appetite

Jun 16, 2025
Max Holloway predicts quick finish in UFC 317 main event between two of his former opponents

Max Holloway predicts quick finish in UFC 317 main event between two of his former opponents

Jun 26, 2025
Jeremiah Fears Rises From Underrated High School Recruit to Top Draft Projection

Jeremiah Fears Rises From Underrated High School Recruit to Top Draft Projection

Jun 25, 2025
We use cookies to help provide you with the best experience when you visit our websites. By using this site you consent to the use of cookies on your device. see our cookie policy.